2023 Fraud, Waste & Abuse and HIPAA Compliance Program Updates
The PAAS National® FWA/HIPAA Compliance Program has implemented changes to ensure pharmacies continue to have a robust program in place.
Entries by Trent Thiede, PharmD, MBA
Pharmacy to Pharmacy Inventory Transfers – Buyer Beware!
Pharmacy to pharmacy transfers are commonplace in the industry, but much has changed since Lipitor® and Prevacid® were used as currency in a legal drug exchange.
Use and Posting of Guidance Documents by DEA – What’s Changed with Controlled Substance Annotations?
On June 23, 2022 the Drug Enforcement Agency (DEA) created a Guidance Document about the use and posting of guidance documents by the DEA (yes, a guidance document about guidance documents).
Beware: DEA and Wholesalers are Cracking Down on Controlled Substance Dispensing
Take note – the DEA is coming after pharmacies dispensing illegitimate controlled substance prescriptions. Pharmacists should all be aware of their corresponding responsibility and the need for a legitimate medical purpose when dispensing controlled substance prescriptions.
Understanding Caremark’s Restrictions on Bulk Purchases
Community pharmacies have been fed up with PBM antics for a long time. Egregious audits, absurd DIR fees, arduous credentialing requirements, unconscionable contracts; we run out of adjectives before we run out of PBM issues.
Audit Risk: Ivermectin Used for Treating COVID-19 (September Update)
Dangers of using Ivermectin to treat or prevent COVID-19. PAAS is seeing more PBM audits on ivermectin prescriptions. Pharmacies should be prepared!
FDA Guidance on Insulin Pens Puzzling
On October 13, 2020, the U.S. Food and Drug Administration issued a statement looking to clarify the intent of the November 2019 label revisions for insulin pens.
Smartphones Put Pharmacies at Risk for Inappropriate PHI Disclosures
Smartphone utilization has, unfortunately, become pervasive with patient interactions. Patients on their phone while trying to consult on new medications, or a patient snapchatting a friend while waiting for their prescription to be filled is all too common.
COVID-19 Audit Considerations Follow-Up
On April 3, 2020, PAAS National® sent an urgent email alert to all members discussing COVID-19 audit considerations. This email came as a result of our desire to help pharmacies on the frontlines of this pandemic.
